A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

Pharmacogenomics

Volumn 5, Issue 8, 2004, Pages 1139-1149

  Phillips, Kathryn A ^a   Van Bebber, Stephanie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness analysis; Economics; Health technology assessment; Pharmacogenomics; Review

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BRCA1 PROTEIN; BRCA2 PROTEIN; GEFITINIB; ORAL CONTRACEPTIVE AGENT; RIBAVIRIN; TRASTUZUMAB; WARFARIN;

ACCURACY; BREAST CANCER; CANCER THERAPY; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG TARGETING; FREQUENCY ANALYSIS; GENE MUTATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; PHARMACOGENOMICS; PROTEIN TARGETING; REVIEW; SYSTEMATIC REVIEW; VIRUS INFECTION;

COST-BENEFIT ANALYSIS; GENE THERAPY; HUMANS; PHARMACOGENETICS;

EID: 11044228905     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.8.1139     Document Type: Review

References (31)

1. Krynetski E, Evans WE: Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22, 7403-7413 (2003).
2. Fuhrmans V: Roche test promises to tailor drugs to patients. Wall Street Journal A3 (2003).
3. Kaiser J: FDA puts the brakes on Roche's gene array test. Science 302, 1134 (2003).
4. Hovey H: Targeted cancer drugs wait in wings. Wall Street Journal D3 (2004).
5. Phillips KA, Veenstra D, Van Bebber SL, Sakowski J: An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4(3), 231-239 (2003).
6. Gold M, Siegel J, Russell L, Weinstein M: Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, USA (1996).
7. Varmus H: Getting ready for gene-based medicine. N. Engl. J. Med. 347(19), 1526-1527 (2002).
8. Sassi F, Archard L, McDaid D: Searching literature databases for healthcare economic evaluations. Med. Care 40(5), 387-394 (2002).
9. Auerbach AD, Sanders GD, Hambleton J: Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am. J. Med. 116, 816-828 (2004).
10. Creinin MD, Lisman R, Strickler RC: Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil. Steril. 72(4), 646-651 (1999).
11. Eckman M, Singh SK, Erban JK, Kao G: Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med. Dec. Making 22, 108-112 (2002).
12. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22(5), 854-863 (2004 ).
13. Marchetti M, Pistorio A, Barosi G: Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden-cost-effectiveness analysis. Thromb. Haemost. 84(5), 752-757 (2000); Erratum in: Thromb. Haemost. 84(6), 1112 (2000).
14. Marchetti M, Quaglini S, Barosi G: Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and promothrombin G20210A. QJM 94, 365-372 (2001).
15. Marra CA, Esdaile JM, Aslam AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29, 2507-2512 (2002).
16. Oh K-T, Anis AH, Bae S-C: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 42, 1-8 (2003).
17. Weinstein M, Goldie S, Losina E et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134(6), 440-450 (2001).
18. Wong JB, Bennett WG, Koff RS, Pauker SG: Pretreatment evaluation of chronic hepatitis C, risks, benefits and costs. JAMA 280(24),2088-2093 (1998).
19. Younossi AM, Singer ME, McHutchison JG, Shermock KM: Cost Effectiveness of interferon α2b Combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30, 1318-1324 (1999).
20. Chou WH, Feng-Xiang Y, de Leon J et al.: Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 20(2), 246-251 (2000).
21. Goldman L, Goldman PA, Williams LW, Weinstein MC: Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J. Cardiol. 72(10), 75D-79D (1993).
22. Phillips KA, Van Bebber SL, Veenstra D, Sakowski J: The economics of pharmacogenomics. Curr. Pharmacogenomics 1(4), 277-284 (2003).
23. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J: Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am. J. Man. Care 10(7), 425-432 (2000).
24. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2(3), E29 (2000).
25. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
26. Zivian MT, Gekoski W, Knox VJ, Larsen W, Hatchette V: Psychotherapy for the elderly: public opinion. Psychotherapy 31(3 , 492-502 (1994).
27. Stratton MR, Futreal PA: Understanding the target. Nature 430, 30 (2004).
28. Phillips KA, Van Bebber SL: Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med. Care Res. Rev. (2004) (Submitted).
29. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
30. Gillick MR: Medicare coverage for technological innovations - time for new criteria? N. Engl. J. Med. 350(21), 2199-2203 (2004).
31. Phillips KA, Van Bebber SL: Where could generic testing to individualize drug therapies have the greatest impact? the example of genetic testing for CYP2D6 variant alleles. JAMA (2004) (Submitted).